A detailed history of Apriem Advisors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Apriem Advisors holds 15,527 shares of REGN stock, worth $10.9 Million. This represents 1.92% of its overall portfolio holdings.

Number of Shares
15,527
Previous 16,333 4.93%
Holding current value
$10.9 Million
Previous $17.2 Million 4.92%
% of portfolio
1.92%
Previous 2.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $825,416 - $968,618
-806 Reduced 4.93%
15,527 $16.3 Million
Q2 2024

Aug 14, 2024

SELL
$883.2 - $1071.19 $3.88 Million - $4.7 Million
-4,390 Reduced 21.18%
16,333 $17.2 Million
Q1 2024

May 15, 2024

SELL
$902.69 - $993.35 $2.79 Million - $3.07 Million
-3,095 Reduced 12.99%
20,723 $19.9 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $851,922 - $968,988
-1,099 Reduced 4.41%
23,818 $20.9 Million
Q3 2023

Nov 13, 2023

SELL
$692.45 - $844.37 $474,328 - $578,393
-685 Reduced 2.68%
24,917 $20.5 Million
Q2 2023

Aug 08, 2023

SELL
$700.03 - $830.35 $353,515 - $419,326
-505 Reduced 1.93%
25,602 $18.4 Million
Q1 2023

May 12, 2023

SELL
$680.49 - $826.97 $3.58 Million - $4.35 Million
-5,265 Reduced 16.78%
26,107 $21.5 Million
Q4 2022

Feb 13, 2023

SELL
$705.89 - $766.39 $618,359 - $671,357
-876 Reduced 2.72%
31,372 $22.6 Million
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $16,071 - $20,280
28 Added 0.09%
32,248 $22.2 Million
Q2 2022

Aug 08, 2022

BUY
$548.35 - $738.84 $44,964 - $60,584
82 Added 0.26%
32,220 $19 Million
Q1 2022

May 10, 2022

BUY
$595.12 - $698.43 $229,716 - $269,593
386 Added 1.22%
32,138 $22.4 Million
Q4 2021

Feb 09, 2022

BUY
$543.48 - $670.97 $17.3 Million - $21.3 Million
31,752 New
31,752 $20.1 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Apriem Advisors Portfolio

Follow Apriem Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apriem Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Apriem Advisors with notifications on news.